Phase 4Completed
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
- Sponsor
- Pfizer (Industry)
- Enrollment
- 4,372 enrolled
- Conditions
- Arthritis, Rheumatoid
- Interventions
- tofacitinib; tofacitinib; adalimumab; etanercept
- Ages
- adults, older adults
- Registry
- NCT02092467, EUCTR2013-003177-99
Full record on ClinicalTrials.gov
From the registry
This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.
Primary outcomes
- Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)
- Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)
History
Results first posted
Last registry update
Primary completion
Registered
Started